不用本金就能赚钱的方法

来宝网Logo

热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

现在位置不用本金就能赚钱的方法>技术资料不用本金就能赚钱的方法>行业动态>公司动态>安进与安斯泰来成立合资公司Amgen-Astellas BioPharma KK

安进与安斯泰来成立合资公司Amgen-Astellas BioPharma KK

Amgen2013年5月31日 13:30 点击:1581

美国安进公司(Amgen)   日本,安斯泰来,Astellas,


2013年5月29日,全球最大的独立型生物技术公司——安进(Amgen)和日本制药公司安斯泰来(Astellas)联合宣布,双方已达成了战略联盟,开发新的药物以满足日本患者严重未满足的医疗需求。

GAILIANMENGJIANGTONGGUOXINDESHANGYEMOSHICHONGFENLIYONGSHUANGFANGDEHUBUNENGLI。GAIMOSHIZHIZAIJIANGAmgenGUANXIANZHONGDEHOUXUANYAOWUYUAstellasDUIRIBENHUANZHEJIYISHENGXUQIUDELEJIE、ZAIRIBENZHANGQIDESHANGYEJINGYANHEJIANGUANJINGYAN、JIQIZUOWEILINGXIANZHIYAOGONGSIZAIRIBENDEQIANGDACUNZAIJIEHEQILAI。

不用本金就能赚钱的方法AmgenGUANLICENGCENGZAI2YUEFENTOUZIZHEHEFENXISHIHUIYISHANGXUANBU,JIHUAZAI2015HE2016NIANJIANGQIYEWUKUODAZHIYAZHOUZHUYAOSHICHANG,TONGSHIXUANCHENGQIZAIRIBENHEZHONGGUOSHICHANGQUEFACUNZAI,SHIYIGEHENMINGXIANDEQUEKOU。

不用本金就能赚钱的方法GAILIANMENGDESHOUGEYUANSUSHISHUANGFANGZHIJIANDEYIXIANGZHANGQIHEZUO,GAIHEZUODEZHONGDIANSHIZAIRIBENGONGTONGKAIFAJIGONGTONGSHANGYEHUAAmgenGUANXIANZHONGDE5ZHONGHOUXUANYAOWU,BAOKUO4ZHONGSHENGWUZHIJIHE1ZHONGXIAOFENZIYAOWU,KAIFAYONGYUXINXUEGUAN、GUGEJIBING、AIZHENGDEZHILIAO,YUJISHOUGEYAOWUJIANGYU2016NIANZAIRIBENSHANGSHI。

不用本金就能赚钱的方法LIANMENGDEDI2GEYUANSUSHI,SHUANGFANGZAIRIBENDONGJINGCHENGLIYIJIAHEZIGONGSI,TONGGUOGAIHEZIGONGSI,SHUANGFANGJIANGXIESHOUHEZUO,SHIAmgenXUNSUJIANLIZAIRIBENDEDIMIANNENGLI(on-the-ground capabilities)。HEZIGONGSIDEMINGCHENGWEIAmgen-Astellas BioPharma KK,YOUEiichi TakahashiDANRENZONGJINGLI,QIYUGUANLIZHIWEIJIANGYOUAmgenHEAstellasWEIREN,GAIGONGSIJIANGYU2013NIAN10YUE1RIKAISHIYUNYING,BINGSUIZHEZHANGQIHEZUODEJIXU,ZUIKUAIYU2020NIANCHENGWEIAmgenQUANZIZIGONGSI。

不用本金就能赚钱的方法GAILIANMENGJIANGYOUZHUYUJIAKUAIAmgenGUANXIANYAOWUZAIRIBENDEKAIFAJISHANGYEHUA,FANYINGLEAmgenZHILIYURIBENSHICHANGDEZHANGQISHIMING,TONGSHIYESHIAmgenQUANQIUKUOZHANGZHANLVEDEZHONGYAOYIBU。

不用本金就能赚钱的方法CICILIANMENGHEZUOKAIFADE5ZHONGGUANXIANYAOWUFENBIEWEI:

*AMG 145:抗PCSK-9单克隆抗体,开发适应症:高脂血症(Hyperlipidemia),开发进程:全球(III期),日本(II期);
*Romosozumab(AMG 785):抗硬化蛋白(Sclerostin)单克隆抗体,开发适应症:骨质疏松(Osteoporosis),开发进程:全球(III期),日本(II/III期);
*Rilotumumab(AMG 102):抗HGF单克隆抗体,开发适应症:胃癌(Gastric Cancer),开发进程:全球(III期),日本(I期);
*Blinatumomab(AMG 103):抗CD19 BiTE(抗CD19双特异性单链抗体),开发适应症:急性淋巴细胞白血病(ALL)和非霍奇金淋巴瘤(NHL),开发进程:全球(II期),日本(-)
*AMG 337:MET抑制剂,开发适应症:胃癌(Gastric Cancer),开发进程:全球(I期),日本(-)。

 

May. 29, 2013
Amgen And Astellas Announce Japan Alliance
Innovative Joint Venture to Address Unmet Medical Needs of Patients in Japan

THOUSAND OAKS, Calif. and TOKYO, May 29, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN), the world's largest independent biotechnology company, and Astellas Pharma Inc. (Tokyo Stock Exchange: 4503, "Astellas"), a leading Tokyo-based global pharmaceutical company, today announced the companies have entered into a strategic alliance to provide new medicines to help address serious unmet medical needs of Japanese patients.

The alliance leverages the complementary capabilities of both companies through an innovative business model that combines Amgen's pipeline candidates with Astellas' deep knowledge of Japanese patient and physician needs, long-term commercial and regulatory experience, and strong presence as a leading company in Japan.

The first element of the alliance is a long-term collaboration between the two companies that will focus on the co-development and co-commercialization in Japan of five Amgen pipeline medicines. The five medicines, which include four biologics and one small molecule, are focused on the treatment of cardiovascular and bone diseases and cancer. The pipeline medicines range from early to late stages of development in Japan, with the first potential commercial launch expected as early as 2016.

The second element of the alliance is the establishment of a Tokyo-based joint venture company through which the companies will work together to enable Amgen to rapidly build on-the-ground capabilities in Japan. The joint venture will operate under the name Amgen Astellas BioPharma KK and will be led by  Eiichi Takahashi, who will serve as general manager. Additional management roles will be appointed by Amgen and Astellas. The joint venture will be staffed by seconded employees from Astellas, transferred employees from Amgen and newly hired employees. It is expected that the joint venture will start operations on Oct. 1, 2013, and will become a wholly owned Amgen affiliate as soon as 2020 with the long-term collaboration continuing.

"Through this alliance, Amgen will work closely with Astellas to leverage its extensive knowledge of the local market," said  Robert A. Bradway, chairman and chief executive officer atAmgen. "With Astellas' strong capabilities and excellent reputation, this alliance will help accelerate development and commercialization of Amgen medicines for patients in Japan. This alliance reflects our long-term commitment to the Japan market and is an important step in our global expansion efforts."  

"We look forward to entering this alliance with Amgen and believe it will strengthen our pipeline to address unmet medical needs, as well as enable us to obtain growth drivers," said Yoshihiko Hatanaka, president and CEO of Astellas. "We will work closely with Amgen to build the joint venture, which will provide innovative medicines to patients in Japan."

Goldman, Sachs & Co. is acting as financial advisor to Amgen in connection with this transaction. Morrison & Foerster LLP 不用本金就能赚钱的方法served as external legal counsel to Astellas.

Five Amgen Pipeline Medicines Included in the Amgen Astellas Alliance

Molecule

Lead Indication

Mode of Action

Development Stage

Global

Japan

 

AMG 145

 

Hyperlipidemia  

Anti-PCSK-9 mAb

Phase 3

Phase 2

 

Romosozumab

(AMG 785)1

 

Osteoporosis

Anti-Sclerostin mAb

Phase 3

Phase 2/3

 

Rilotumumab

(AMG 102)

 

Gastric Cancer

Anti-HGF mAb

Phase 3

Phase 1

 

AMG 337

 

Gastric Cancer

MET inhibitor

Phase 1


 

 

Blinatumomab

(AMG 103)

 

Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin's Lymphoma (NHL)

Anti-CD19 BiTE®

Phase 2


 

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping people around the world in the fight against serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. For more information, visit  and follow us on .

About Astellas

Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 17,000 employees worldwide. The organization is committed to becoming a global category leader in urology, immunology (including transplantation) and infectious diseases, oncology, neuroscience and DM complications and kidney diseases. For more information on Astellas Pharma Inc., please visit the company website at .

(来源: Amgen )


全年征稿 / 资讯合作

联系邮箱:kefu@strauss-usa.com不用本金就能赚钱的方法

BANQUANYUMIANZESHENGMING

  • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://strauss-usa.com,违反者本网将追究相关法律责任。
  • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
  • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


湖南快乐十分 湖南快乐十分 福建快3走势图0 福建快3走势图 河南快3走势图 河南快3走势图 广东11选5开奖结果 福建11选5走势图